Coronaviruses

References

• Peeri NC, Shrestha N, Rahman MS, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020;49:717–726.
   PubMed Web of Science ®Google Scholar
• Guarner J. Three emerging coronaviruses in two decades. Am J Clin Pathol. 2020;153:420–421.
   PubMed Web of Science ®Google Scholar
• Mori M, Capasso C, Carta F, et al. A deadly spillover: SARS-CoV-2 outbreak. Expert Opin Ther Pat. 2020;30:481–485.
   PubMed Web of Science ®Google Scholar
• Hodcroft EB, De Maio N, Lanfear R, et al. Want to track pandemic variants faster? Fix the bioinformatics bottleneck. Nature. 2021;591:30–33.
   PubMed Web of Science ®Google Scholar
• Zhou B, Thi Nhu Thao T, Hoffmann D, et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature. 2021. (in press). DOI:10.1038/s41586-021-03361-1
   Web of Science ®Google Scholar
• Harper H, Burridge A, Winfield M, et al. Detecting SARS-CoV-2 variants with SNP genotyping. PLoS One. 2021;16:e0243185.
   PubMed Web of Science ®Google Scholar
• Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines (Basel). 2021;9:147.
   PubMed Web of Science ®Google Scholar
• Moore JP. Approaches for optimal use of different COVID-19 vaccines: issues of viral variants and vaccine efficacy. JAMA. 2021. (in press). DOI:10.1001/jama.2021.3465
   PubMed Web of Science ®Google Scholar
• Yadav PD, Ella R, Kumar S, et al. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun. 2021;12(1):1386.
   PubMed Web of Science ®Google Scholar
• Iacobucci G. Covid-19: single dose of Pfizer and Oxford vaccines cuts risk of hospital admission by 80% in over 80s, data suggest. BMJ. 2021;372:n612.
   PubMedGoogle Scholar
• Andreano E, Nicastri E, Paciello I, et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021;S0092-8674(21)00224–5. (in press). DOI:10.1016/j.cell.2021.02.035
   PubMedGoogle Scholar
• Edara VV, Norwood C, Floyd K, et al. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. bioRxiv [Preprint]. 2021 Feb 22:2021.02.20.432046. DOI:10.1101/2021.02.20.432046
   Google Scholar
• Toovey OTR, Harvey KN, Bird PW, et al. Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK. J Infect. 2021;S0163-4453(21)00047–5 (in press). DOI:10.1016/j.jinf.2021.01.025
   Google Scholar
• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19:149–150.
   PubMed Web of Science ®Google Scholar
• FDA approves remdesivir. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
   Google Scholar
• Ma Y, Frutos-Beltrán E, Kang D, et al. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev. 2021. (in press). DOI:10.1039/d0cs01084g
   Google Scholar
• De Clercq E. Fifty years in search of selective antiviral drugs. J Med Chem. 2019;62:7322–7339.
   PubMed Web of Science ®Google Scholar
• Mastrolorenzo A, Rusconi S, Scozzafava A, et al. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem. 2007;14:2734–2748.
   PubMed Web of Science ®Google Scholar
• Barbaro G, Scozzafava A, Mastrolorenzo A, et al. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des. 2005;11:1805–1843.
   PubMed Web of Science ®Google Scholar
• Alazard-Dany N, Denolly S, Boson B, et al. Overview of HCV life cycle with a special focus on current and possible future antiviral targets. Viruses. 2019;11:30.
   Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381–385.
   PubMed Web of Science ®Google Scholar
• Woo PC, Huang Y, Lau SK, et al. Coronavirus genomics and bioinformatics analysis. Viruses. 2010;2:1804–1820.
   PubMed Web of Science ®Google Scholar
• Killerby ME, Biggs HM, Midgley CM, et al. Middle East Respiratory Syndrome Coronavirus transmission. Emerg Infect Dis. 2020;26:191–198.
   PubMed Web of Science ®Google Scholar
• Quammen D. Spillover: animal infections and the next human pandemic. New York: W.W. Norton and Co.; 2012. p. 1–608.
   Google Scholar
• Cusinato J, Cau Y, Calvani AM, et al. Repurposing drugs for the management of COVID-19. Expert Opin Ther Pat. 2021. (in press). DOI:10.1080/13543776.2021.1861248
   Web of Science ®Google Scholar
• Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat. 2021. (in press). DOI:10.1080/13543776.2021.1880568
   PubMed Web of Science ®Google Scholar
• Spratt AN, Gallazzi F, Quinn TP, et al. Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents. Expert Opin Ther Pat. 2021. (in press). DOI:10.1080/13543776.2021.1884224
   PubMedGoogle Scholar
• Capasso C, Nocentini A, Supuran CT. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses. Expert Opin Ther Pat. 2021. (in press). DOI:10.1080/13543776.2021.1857726
   Web of Science ®Google Scholar
• Atanasov AG, Zotchev SB, Dirsch VM, et al. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20:200–216.
   PubMed Web of Science ®Google Scholar
• Carta F, Birkmann A, Pfaff T, et al. Lead development of thiazolylsulfonamides with carbonic anhydrase inhibitory action. J Med Chem. 2017;60:3154–3164.
   PubMed Web of Science ®Google Scholar
• Pritelivir approval. Available from: https://ichgcp.net/clinical-trials-registry/NCT03073967
   Google Scholar
• Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev. 2020;40:2485–2565.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem. 2021;36:561–580.
   PubMed Web of Science ®Google Scholar
• Gupta A, Madhavan MV, Poterucha TJ, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun. 2021;12:1325.
   PubMed Web of Science ®Google Scholar
• Marić I, Oskotsky T, Kosti I, et al. Decreased mortality rate among COVID-19 patients prescribed statins: data from electronic health records in the US. Front Med (Lausanne). 2021;8:639804.
   PubMed Web of Science ®Google Scholar
• Permana H, Huang I, Purwiga A, et al. In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis. Pharmacol Rep. 2021. (in press). DOI:10.1007/s43440-021-00233-3
   PubMed Web of Science ®Google Scholar